fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-03-04 III Result   Sanofi-Aventis (France) Cabazitaxel (novel investigational taxane) metastatic hormone-refractory prostate cancer 26 countries See details
2010-03-01 Other Result Actelion (Switzerland)   bosentan idiopathic pulmonary fibrosis   See details
2010-02-26 II Result Agennix (Germany)   talactoferrin severe sepsis USA See details
2010-02-25 III Result Paion (Germany) Lundbeck (Denmark) desmoteplase (genetically engineered version of a clot dissolving protein found in the saliva of the vampire bat Desmodus rotundus) ischaemic stroke   See details
2010-02-24 I-II Launch Généthon (France)   gene therapy based on a ex vivo approach that uses an HIV-derived lentiviral vector to transfer genes into autologous CD34+ hematopoietic stem cells from the patient. Wiskott-Aldrich syndrome France, UK See details
2010-02-23 I Result Galapagos (Belgium)   GLPG0259 rheumatoid arthritis   See details
2010-02-23 I Launch GlycoVaxyn (Switzerland)   Shigella vaccine GVXN SD133 (The vaccine consists of a polysaccharide of Shigella dysenteriae O1 conjugated to a protein carrier) Shigella dysenteriae   See details
2010-02-22 III Result Biotec Pharmacon (Norway)   soluble beta-glucan (SBG) oral mucositis   See details
2010-02-18 II Result Regeneron Pharmaceuticals (USA) Bayer HealthCare (Germany) VEGF Trap-Eye® (human soluble VEGF receptor fusion protein) Diabetic macular edema   See details
2010-02-15 III Result ALK-Abelló (Denmark) Merck &Co (USA) Grazax®(GT-14 tablet based immunotherapy) pollen allergies USA See details
2010-02-11 I Result Intercell (Austria)   IC47 (This vaccine candidate is a recombinant subunit vaccine consisting of three conserved surface proteins from Streptococcus pneumoniae. Two of these proteins were discovered using Intercell's proprietary Antigen Identification Program (AIP®), while the third was in-licensed from the U.S. Centers for Disease Control and Prevention (CDC).) disease caused by Streptococcus pneumoniae   See details
2010-02-11 Other Result 4SC (Germany)   4SC-205 (oral inhibitor of the kinesin spindle protein Eg5 (also known as kinesin-5, KIF11), a motor protein that interacts with microtubules, a component of the cellular mitosis machinery, and mediates the segregation of the two spindle poles resulting in the correct distribution of the chromosomes to the daughter cells) Inhibition of Eg5 leads to cell cycle arrest by interfering with microtubules, leading to apoptosis (programmed cell death). solid tumours or malignant lymphomas Germany See details
2010-02-11 III Result   Roche (Switzerland) taspoglutide (glucagon-like-peptide-1 (GLP-1) analogue) Roche exercised its licensing option for taspoglutide from Ipsen in 2006 and acquired exclusive worldwide rights to develop and market taspoglutide, except in Japan where these rights are shared with Teijin and in France where Ipsen retained co-marketing rights. type 2 diabetes   See details
2010-02-04 I Result 7TM(Denmark)   TM38837 (first in class, second generation CB1 receptor antagonist discovered internally) obesity and related metabolic disorders   See details
2010-02-04 I Launch Paion(Germany) Ono Pharmaceutical (Japan) CNS 7056 (ONO-2745) induction and maintenance of anaesthesia   See details
[<<]      «      2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12      »      [57]